{
    "nctId": "NCT06476119",
    "briefTitle": "OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes",
    "officialTitle": "OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer Stage I, Triple Negative Breast Cancer (TNBC)",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 490,
    "primaryOutcomeMeasure": "Disease recurrence Free Interval (DRFI) - optimalisation cohort per-protocol population",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female or male patients;\n* \\>=18 years;\n* Written informed consent;\n* TNBC (defined as: invasive carcinoma; ER/PR expression 0-9%; Human Epidermal Growth Factor Receptor 2 \\[HER2\\] negative \\[0, 1+ or 2+ on immunohistochemistry, without HER2 amplification on in-situ hybridization\\]) on the diagnostic biopsy and the surgical specimen;\n* Pathological stage I TNBC (according to the TNM staging 8th edition):\n\n  * pT1a/b/c (\u22642 cm), confirmed by an invasive component of \u22642 cm on the surgical specimen (microinvasive disease \\[pT1mi, \u22641 mm) is not allowed);\n  * pN0, confirmed by absence of malignant cells in the sentinel lymph node or any other lymph node after surgery (isolated tumor cells \\[N0(i+)\\] are not allowed);\n* No evidence of nodal or distant metastases (cN0M0) on pre and/or postoperative imaging examinations (performed following local/national guidelines, but must include an 18F-fluorodeoxyglucose positron emission tomography/computed tomography \\[18F-FDG-PET/CT, at least from skull base to upper legs\\] or computed tomography \\[CT\\] of neck/chest/abdomen/pelvis \\[CT only if 18F-FDG-PET/CT would not be available; 18F-FDG-PET/CT mandatory in the Netherlands\\]);\n* sTIL score of \u226550% for patients \u226540 years at the time of TNBC diagnosis and \u226575% for patients \\<40 years at the time of TNBC diagnosis on an H\\&E FFPE tissue slide on the surgical specimen, according to International Immuno-Oncology Biomarker Working Group on Breast Cancer (formerly International TILs Working Group) guidelines, by local and central review\n* Has undergone curative breast surgery (breast-conserving surgery or mastectomy and surgical axillary staging \\[including at least sentinel lymph node procedure\\]);\n* Absence of recurrence between curative breast surgery and expression of patient preference;\n* Eligible for radiotherapy (if indicated).\n\nExclusion Criteria:\n\n* Prior disease history of invasive and/or non-invasive breast cancer, or ongoing treatment for invasive and/or non-invasive breast cancer;\n* Multifocal, multicentric or bilateral breast cancer at the time of screening;\n* Administration of neoadjuvant systemic therapy;\n* Presence of lymphovascular invasion on the diagnostic biopsy and/or the surgical specimen;\n* Other invasive malignancy within 5 years prior to inclusion, with the exception of ade-quately treated non-melanoma skin cancer, localized cervical cancer, localized and Gleason \u22646 prostate cancer;\n* Uncontrolled severe illness or medical condition;\n* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the in the trial.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}